86 related articles for article (PubMed ID: 22380736)
1. Discovery of highly potent and selective pan-Aurora kinase inhibitors with enhanced in vivo antitumor therapeutic index.
Liu G; Abraham S; Tran L; Vickers TD; Xu S; Hadd MJ; Quiambao S; Holladay MW; Hua H; Ford Pulido JM; Gunawardane RN; Davis MI; Eichelberger SR; Apuy JL; Gitnick D; Gardner MF; James J; Breider MA; Belli B; Armstrong RC; Treiber DK
J Med Chem; 2012 Apr; 55(7):3250-60. PubMed ID: 22380736
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
[TBL] [Abstract][Full Text] [Related]
3. Discovery of GSK1070916, a potent and selective inhibitor of Aurora B/C kinase.
Adams ND; Adams JL; Burgess JL; Chaudhari AM; Copeland RA; Donatelli CA; Drewry DH; Fisher KE; Hamajima T; Hardwicke MA; Huffman WF; Koretke-Brown KK; Lai ZV; McDonald OB; Nakamura H; Newlander KA; Oleykowski CA; Parrish CA; Patrick DR; Plant R; Sarpong MA; Sasaki K; Schmidt SJ; Silva DJ; Sutton D; Tang J; Thompson CS; Tummino PJ; Wang JC; Xiang H; Yang J; Dhanak D
J Med Chem; 2010 May; 53(10):3973-4001. PubMed ID: 20420387
[TBL] [Abstract][Full Text] [Related]
4. Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
Kerekes AD; Esposite SJ; Doll RJ; Tagat JR; Yu T; Xiao Y; Zhang Y; Prelusky DB; Tevar S; Gray K; Terracina GA; Lee S; Jones J; Liu M; Basso AD; Smith EB
J Med Chem; 2011 Jan; 54(1):201-10. PubMed ID: 21128646
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrrole-indoline-2-ones as Aurora kinase inhibitors with a different inhibition profile.
Chiang CC; Lin YH; Lin SF; Lai CL; Liu C; Wei WY; Yang SC; Wang RW; Teng LW; Chuang SH; Chang JM; Yuan TT; Lee YS; Chen P; Chi WK; Yang JY; Huang HJ; Liao CB; Huang JJ
J Med Chem; 2010 Aug; 53(16):5929-41. PubMed ID: 20681538
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors.
Jung FH; Pasquet G; Lambert-van der Brempt C; Lohmann JJ; Warin N; Renaud F; Germain H; De Savi C; Roberts N; Johnson T; Dousson C; Hill GB; Mortlock AA; Heron N; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Green S; Brown E; Thompson K; Brightwell S
J Med Chem; 2006 Feb; 49(3):955-70. PubMed ID: 16451062
[TBL] [Abstract][Full Text] [Related]
7. SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo.
Arbitrario JP; Belmont BJ; Evanchik MJ; Flanagan WM; Fucini RV; Hansen SK; Harris SO; Hashash A; Hoch U; Hogan JN; Howlett AR; Jacobs JW; Lam JW; Ritchie SC; Romanowski MJ; Silverman JA; Stockett DE; Teague JN; Zimmerman KM; Taverna P
Cancer Chemother Pharmacol; 2010 Mar; 65(4):707-17. PubMed ID: 19649632
[TBL] [Abstract][Full Text] [Related]
8. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
[TBL] [Abstract][Full Text] [Related]
9. Thieno[3,2-c]pyrazoles: a novel class of Aurora inhibitors with favorable antitumor activity.
Bindi S; Fancelli D; Alli C; Berta D; Bertrand JA; Cameron AD; Cappella P; Carpinelli P; Cervi G; Croci V; D'Anello M; Forte B; Giorgini ML; Marsiglio A; Moll J; Pesenti E; Pittalà V; Pulici M; Riccardi-Sirtori F; Roletto F; Soncini C; Storici P; Varasi M; Volpi D; Zugnoni P; Vianello P
Bioorg Med Chem; 2010 Oct; 18(19):7113-20. PubMed ID: 20817473
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905).
Duffey MO; Vos TJ; Adams R; Alley J; Anthony J; Barrett C; Bharathan I; Bowman D; Bump NJ; Chau R; Cullis C; Driscoll DL; Elder A; Forsyth N; Frazer J; Guo J; Guo L; Hyer ML; Janowick D; Kulkarni B; Lai SJ; Lasky K; Li G; Li J; Liao D; Little J; Peng B; Qian MG; Reynolds DJ; Rezaei M; Scott MP; Sells TB; Shinde V; Shi QJ; Sintchak MD; Soucy F; Sprott KT; Stroud SG; Nestor M; Visiers I; Weatherhead G; Ye Y; D'Amore N
J Med Chem; 2012 Jan; 55(1):197-208. PubMed ID: 22070629
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent and selective aurora kinase inhibitor.
Oslob JD; Romanowski MJ; Allen DA; Baskaran S; Bui M; Elling RA; Flanagan WM; Fung AD; Hanan EJ; Harris S; Heumann SA; Hoch U; Jacobs JW; Lam J; Lawrence CE; McDowell RS; Nannini MA; Shen W; Silverman JA; Sopko MM; Tangonan BT; Teague J; Yoburn JC; Yu CH; Zhong M; Zimmerman KM; O'Brien T; Lew W
Bioorg Med Chem Lett; 2008 Sep; 18(17):4880-4. PubMed ID: 18678489
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol 3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3,5-triazin-2-yl]-1H-benzimidazole (ZSTK474).
Rewcastle GW; Gamage SA; Flanagan JU; Frederick R; Denny WA; Baguley BC; Kestell P; Singh R; Kendall JD; Marshall ES; Lill CL; Lee WJ; Kolekar S; Buchanan CM; Jamieson SM; Shepherd PR
J Med Chem; 2011 Oct; 54(20):7105-26. PubMed ID: 21882832
[TBL] [Abstract][Full Text] [Related]
13. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
[TBL] [Abstract][Full Text] [Related]
14. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors.
Medina JR; Becker CJ; Blackledge CW; Duquenne C; Feng Y; Grant SW; Heerding D; Li WH; Miller WH; Romeril SP; Scherzer D; Shu A; Bobko MA; Chadderton AR; Dumble M; Gardiner CM; Gilbert S; Liu Q; Rabindran SK; Sudakin V; Xiang H; Brady PG; Campobasso N; Ward P; Axten JM
J Med Chem; 2011 Mar; 54(6):1871-95. PubMed ID: 21341675
[TBL] [Abstract][Full Text] [Related]
16. Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.
Mortlock AA; Foote KM; Heron NM; Jung FH; Pasquet G; Lohmann JJ; Warin N; Renaud F; De Savi C; Roberts NJ; Johnson T; Dousson CB; Hill GB; Perkins D; Hatter G; Wilkinson RW; Wedge SR; Heaton SP; Odedra R; Keen NJ; Crafter C; Brown E; Thompson K; Brightwell S; Khatri L; Brady MC; Kearney S; McKillop D; Rhead S; Parry T; Green S
J Med Chem; 2007 May; 50(9):2213-24. PubMed ID: 17373783
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.
Manfredi MG; Ecsedy JA; Chakravarty A; Silverman L; Zhang M; Hoar KM; Stroud SG; Chen W; Shinde V; Huck JJ; Wysong DR; Janowick DA; Hyer ML; Leroy PJ; Gershman RE; Silva MD; Germanos MS; Bolen JB; Claiborne CF; Sells TB
Clin Cancer Res; 2011 Dec; 17(24):7614-24. PubMed ID: 22016509
[TBL] [Abstract][Full Text] [Related]
18. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
[TBL] [Abstract][Full Text] [Related]
19. Novel potent orally active multitargeted receptor tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of 2-indolinone derivatives.
Cho TP; Dong SY; Jun F; Hong FJ; Liang YJ; Lu X; Hua PJ; Li LY; Lei Z; Bing H; Ying Z; Qiong LF; Bei FB; Guang LL; Shen GA; Hong SG; Hong SW; Tai MX
J Med Chem; 2010 Nov; 53(22):8140-9. PubMed ID: 21028894
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
